3,635,411 Shares in Quanterix Corporation $QTRX Bought by BlackRock Inc.

Key Points

• BlackRock acquired 3.64 million Quanterix shares during the second quarter, worth approximately $15.7 million and representing about 7.72% of the company. Institutional investors collectively own 86.48% of QTRX.
• Quanterix reported weaker-than-expected quarterly results, posting a loss of $1.04 per share versus the $0.41 consensus estimate and revenue of $32.91 million compared with expectations of $37.48 million.
• Analyst sentiment remains negative: Quanterix has an average “Reduce” rating and a $3.00 target price, while the stock recently traded at $2.58 after declining 1.1%.

BlackRock Inc. bought a new position in shares of Quanterix Corporation (NASDAQ:QTRX - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 3,635,411 shares of the company's stock, valued at approximately $15,705,000. BlackRock Inc. owned about 7.72% of Quanterix as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also modified their holdings of QTRX. Farther Finance Advisors LLC bought a new stake in shares of Quanterix in the 4th quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Quanterix during the fourth quarter valued at $27,000. Quarry LP boosted its holdings in shares of Quanterix by 277,300.0% during the third quarter. Quarry LP now owns 5,548 shares of the company's stock valued at $30,000 after acquiring an additional 5,546 shares during the period. AXQ Capital LP bought a new position in shares of Quanterix during the fourth quarter worth about $70,000. Finally, Renaissance Technologies LLC bought a new position in shares of Quanterix during the fourth quarter worth about $75,000. Institutional investors and hedge funds own 86.48% of the company's stock.

Quanterix Stock Down 1.1%

NASDAQ:QTRX opened at $2.58 on Friday. Quanterix Corporation has a 1-year low of $2.15 and a 1-year high of $8.77. The stock has a fifty day simple moving average of $3.48 and a 200 day simple moving average of $3.71. The firm has a market capitalization of $122.01 million, a price-to-earnings ratio of -0.98 and a beta of 1.04.

Quanterix (NASDAQ:QTRX - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.63). The business had revenue of $32.91 million during the quarter, compared to analyst estimates of $37.48 million. Quanterix had a negative return on equity of 26.09% and a negative net margin of 80.25%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on QTRX shares. Canaccord Genuity Group lowered their target price on Quanterix from $4.00 to $3.00 and set a "hold" rating on the stock in a research report on Monday, August 17th. Weiss Ratings reissued a "sell (e+)" rating on shares of Quanterix in a research note on Friday, August 7th. TD Cowen lowered their price target on Quanterix from $4.00 to $3.00 and set a "hold" rating on the stock in a report on Tuesday, August 11th. Finally, Wall Street Zen cut shares of Quanterix from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Quanterix currently has an average rating of "Reduce" and an average target price of $3.00.

Quanterix Company Profile

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company's core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source